For more than a decade, this is usually the time period when companies tout the steps they’re taking to lower carbon ...

We speak with the Co-Chair of The Left Group in the European Parliament, French MEP Manon Aubry. A noted advocate for ...

A Connecticut doctor who is an expert in his field said it is “one of the silent diseases that does not get the respect it ...

Amitesh Rao, CEO of Leo South Asia, defines success as daily reinvention, driven by strategic depth, capability expansion, ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

President Donald Trump’s pick to be the next U.S. surgeon general has repeatedly said the nation’s medical, health and food ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

Multiple allies caught in the middle of the implosion between President Donald Trump and Elon Musk were delicately attempting ...

Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized ...